title: Condyloma eradication: self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations--an integrated safety assessment.
abstract: Topical application of podophyllin solution, long considered the therapy of first choice against condylomata acuminata, can no longer be recommended due to its low efficacy and gross toxicity. Self-treatment with 0.15-0.5% purified podophyllotoxin preparations, applied twice daily for 3 days, is now advocated as the alternative first-line therapy of choice, when significant improvement is conveniently, and cost-effectively, accomplished within a few weeks. This review provides a summary of the comparative efficacy and utility of podophyllin versus podophyllotoxin as well as a compilation of in vivo and in vitro safety evaluations. In light of overwhelming safety and efficacy data in favor of podophyllotoxin-derived products, it is concluded that podophyllin preparations have no place in the modern treatment portfolio for anogenital warts.
authors.affiliation: Stiefel Laboratories R&D, Holtspur Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0AU, United Kingdom.
authors.forename: E
authors.initials: E
authors.lastname: Longstaff
authors.forename: G
authors.initials: G
authors.lastname: von Krogh
mesh_terms: D000287:Administration, Topical; D000818:Animals; D002415:Cats; D002986:Clinical Trials as Topic; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000453:epidemiology; D019317:Evidence-Based Medicine; D006168:Guinea Pigs; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000633:toxicity*; D051379:Mice; D009152:Mutagenicity Tests; D011033:Podophyllin / Q000008:administration & dosage / Q000633:toxicity*; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000633:toxicity*; D017410:Practice Guidelines as Topic; D011817:Rabbits; D051381:Rats; D012098:Reproduction / Q000187:drug effects; D018675:Toxicity Tests
chemical_list: D007641:Keratolytic Agents; D011033:Podophyllin; D011034:Podophyllotoxin